Travere Therapeutics, INC Form 4 insider transactions

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, reports acquisition of shares through vested performance stock units and a sale to cover tax obligations following FDA approval of FILSPARI.

Travere Therapeutics' CFO, Christopher R. Cline, reports acquisition and disposal of company stock following the FDA's full approval of FILSPARI for IgA Nephropathy.

Christopher R. Cline, CFO of Travere Therapeutics, sold 514 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Director Ron Squarer reported acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 8, 2024.

Director John A. Orwin acquired 6,500 shares of common stock and options to purchase 19,500 shares of Travere Therapeutics, Inc. on May 8, 2024.

Director Brinkley Ruth Williams reports acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc.

Director Sandra Poole reported acquiring shares and options in Travere Therapeutics under the company's equity incentive plan.

Jeffrey A. Meckler, a director of Travere Therapeutics, acquired 6,500 shares of common stock and options to purchase 19,500 shares under the company's 2018 Equity Incentive Plan.

Gary A. Lyons, a director at Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 8, 2024.

Director Timothy Coughlin reports acquisition of shares and stock options in Travere Therapeutics under the company's equity incentive plan.

Director Suzanne Bruhn reported acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 8, 2024, as part of the company's equity incentive plan.

Director Roy D. Baynes reported acquiring shares and stock options in Travere Therapeutics, Inc. on May 8, 2024, according to a Form 4 filing.

Christopher R. Cline, CFO of Travere Therapeutics, sold 54 shares of common stock on April 11, 2024, to cover tax withholding obligations related to vested restricted stock units.